CAS: 97802-53-4

Hexadecenyl-2-hydroxy-sn-glycero-3-PC (C16(Plasm) LPC) is a phosphatidylcholine. It can extend the lag phase of α-synuclein aggregation, making it valuable for Parkinson's disease research.

C16(Plasm) LPC is a lysophosphatidylcholine, a type of lysophospholipid derived predominantly from plasma membrane phospholipids. It originates from the enzymatic action of phospholipase A2, which cleaves the fatty acid chain, typically at the sn-2 position. This leaves behind the lysophospholipid with a single acyl chain. LPC serves as a bioactive signaling molecule, facilitating cellular communication by acting on G protein-coupled receptors and influencing immune cell activity. It can act as an emulsifying agent in biochemical reactions and influence lipid metabolism. LPC is also involved in the regulation of inflammatory responses and is implicated in pathophysiological conditions such as atherosclerosis and metabolic syndrome. Its presence and abundance can serve as biomarkers for various diseases, and it plays roles in the modulation of endothelial cell function, smooth muscle activity, and oxidative stress response. In research applications, C16(Plasm) LPC is used to study cell signaling pathways, particularly in the context of inflammation and metabolic diseases. The product serves as a valuable tool for scientists investigating lipid-mediated signaling mechanisms and their broader physiological implications.